View Older Stories View More Recent Stories

Oct 8, 2024 09:20AM Lexaria Updates Current GLP-1 Market
Oct 1, 2024 09:27AM Lexaria Bioscience (LEXX) Appoints Michael Shankman as Chief Financial Officer
Oct 1, 2024 09:25AM Lexaria Appoints Michael Shankman as Chief Financial Officer
Oct 1, 2024 08:59AM Lexaria Bioscience (LEXX) Appoints Michael Shankman as CFO
Sep 27, 2024 09:24AM Lexaria Bioscience (LEXX) Receives Independent Review Board Approval to Begin Human Pilot Study #3
Sep 27, 2024 09:20AM Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Sep 5, 2024 10:00AM Lexaria Releases Strategic Letter from the Outgoing CEO
Sep 5, 2024 09:07AM Lexaria Bioscience (LEXX) Welcomes Industry Veteran as New CEO
Sep 5, 2024 09:05AM Lexaria Bioscience (LEXX) Appoints Richard Christopher as CEO
Sep 5, 2024 09:00AM Lexaria Welcomes Industry Veteran as New CEO
Sep 3, 2024 08:34AM Lexaria Bioscience (LEXX) Enters a Material Transfer Agreement for DehydraTECH Research
Sep 3, 2024 08:30AM Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Aug 29, 2024 09:28AM Lexaria Bioscience (LEXX) Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Aug 29, 2024 09:25AM Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Aug 27, 2024 09:21AM Lexaria Bioscience (LEXX): First Results From Lexaria's Second GLP-1 Human Pilot Study
Aug 27, 2024 09:20AM First Results from Lexaria's Second GLP-1 Human Pilot Study
Aug 22, 2024 09:23AM Lexaria Bioscience (LEXX): Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Aug 22, 2024 09:20AM Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Aug 21, 2024 09:17AM Lexaria Bioscience (LEXX): Positive Interim Blood Sugar Results From Lexaria's GLP-1 Diabetes Animal Study
Aug 21, 2024 09:00AM Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Aug 19, 2024 09:08AM Lexaria Bioscience (LEXX) Announces Positive Results from Molecular Characterization Study
Aug 19, 2024 09:05AM Positive Results from Lexaria's Molecular Characterization Study
Jul 19, 2024 10:02AM H.C. Wainwright Reiterates Buy Rating on Lexaria Bioscience (LEXX)
Jul 17, 2024 10:33AM Lexaria Bioscience (LEXX) Reports Positive Interim Body Weight Results from Diabetes Animal Study
Jul 17, 2024 10:30AM Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Jul 16, 2024 09:50AM Lexaria Bioscience (LEXX) Preparing For Strategic Growth
Jul 16, 2024 09:22AM Lexaria Bioscience (LEXX) Announces Plans for Growth
Jul 16, 2024 09:20AM Lexaria Preparing For Strategic Growth
Jul 10, 2024 06:43AM H.C. Wainwright Starts Lexaria Bioscience (LEXX) at Buy
Jul 9, 2024 09:10AM Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Jul 8, 2024 09:13AM Lexaria Bioscience (LEXX) Receives New Patents for Antiviral Drug Delivery and for Treating Epilepsy
Jul 8, 2024 09:10AM Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Jun 18, 2024 09:00AM Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
View More Recent Stories View Older Stories